- Conditions
- Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion, Cortisol Excess, Cortisol; Hypersecretion, Cortisol Overproduction, Ectopic ACTH Secretion
- Interventions
- SPI-62, Placebo
- Drug
- Lead sponsor
- Sparrow Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Fort Myers, Florida • Rochester, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced May 21, 2026, 9:06 PM EDT